Published Oct 30, 2026, 11:53 AM ET · Updated 14 days ago · 1 source
Gilead-Backed Aspen Neuroscience Shares Decline 2% After US IPO
bloomberg
·
Original Report
Aspen Neuroscience Inc., a clinical-stage developer of cell therapies, fell 2% after raising about $140.6 million in a US initial public offering.